Bicara Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Bicara Therapeutics Inc. (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company dedicated to developing transformative bifunctional therapies for patients with solid tumors. The company's lead program is ficerafusp alfa (formerly BCA101), a first-in-class bifunctional antibody designed to target the tumor microenvironment. Ficerafusp alfa combines an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). This dual-targeting mechanism is engineered to reverse the fibrotic and immune-excluded tumor microenvironment, enabling deeper and more durable anti-tumor responses. The company's primary clinical focus is on recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly HPV-negative disease, which represents a significant unmet medical need.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the development of lead program ficerafusp alfa (formerly BCA101), a first-in-class bifunctional EGFR-directed monoclonal antibody bound to a human TGF-β ligand trap, through the pivotal Phase 2/3 FORTIFI-HN01 trial in first-line recurrent or metastatic HPV-negative HNSCC.
Expected impact: Establish ficerafusp alfa as a cornerstone therapy in HPV-negative head and neck cancer and secure regulatory approval.
Evolving from a clinical-stage R&D organization into a fully fledged commercial biopharmaceutical company by making key executive hires and scaling commercial capabilities.
Expected impact: Build a strong commercial foundation and launch readiness strategy ahead of potential accelerated approval and commercialization of ficerafusp alfa.
Evaluating the therapeutic potential of ficerafusp alfa in other EGFR-expressing solid tumors, including ongoing Phase 1b signal-seeking studies in metastatic colorectal cancer (mCRC).
Expected impact: Unlock the broader blockbuster potential of the bifunctional antibody platform by expanding into additional high-unmet-need oncology indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides Bicara with access to pembrolizumab (Keytruda) for evaluation in combination with ficerafusp alfa in the pivotal Phase 2/3 FORTIFI-HN01 trial and other Phase 1/1b expansion cohorts.
Terms: Bicara sponsors the trials, and Merck provides pembrolizumab.